Towards evidence-based response criteria for cancer immunotherapy

Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Garralda, Elena, Laurie, Scott A., Seymour, Lesley, de Vries, Elisabeth G. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209139/
https://www.ncbi.nlm.nih.gov/pubmed/37225715
http://dx.doi.org/10.1038/s41467-023-38837-3
_version_ 1785046813696327680
author Garralda, Elena
Laurie, Scott A.
Seymour, Lesley
de Vries, Elisabeth G. E.
author_facet Garralda, Elena
Laurie, Scott A.
Seymour, Lesley
de Vries, Elisabeth G. E.
author_sort Garralda, Elena
collection PubMed
description Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included.
format Online
Article
Text
id pubmed-10209139
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102091392023-05-26 Towards evidence-based response criteria for cancer immunotherapy Garralda, Elena Laurie, Scott A. Seymour, Lesley de Vries, Elisabeth G. E. Nat Commun Comment Early detection of immunotherapy-induced tumor response is of major benefit for patients but can be complicated by therapy-induced pseudoprogression. A consensus guideline-iRECIST- was developed as a modification of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1). Here we describe which next steps are required to test its validity and how novel approaches for response criteria might be developed and included. Nature Publishing Group UK 2023-05-24 /pmc/articles/PMC10209139/ /pubmed/37225715 http://dx.doi.org/10.1038/s41467-023-38837-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Comment
Garralda, Elena
Laurie, Scott A.
Seymour, Lesley
de Vries, Elisabeth G. E.
Towards evidence-based response criteria for cancer immunotherapy
title Towards evidence-based response criteria for cancer immunotherapy
title_full Towards evidence-based response criteria for cancer immunotherapy
title_fullStr Towards evidence-based response criteria for cancer immunotherapy
title_full_unstemmed Towards evidence-based response criteria for cancer immunotherapy
title_short Towards evidence-based response criteria for cancer immunotherapy
title_sort towards evidence-based response criteria for cancer immunotherapy
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209139/
https://www.ncbi.nlm.nih.gov/pubmed/37225715
http://dx.doi.org/10.1038/s41467-023-38837-3
work_keys_str_mv AT garraldaelena towardsevidencebasedresponsecriteriaforcancerimmunotherapy
AT lauriescotta towardsevidencebasedresponsecriteriaforcancerimmunotherapy
AT seymourlesley towardsevidencebasedresponsecriteriaforcancerimmunotherapy
AT devrieselisabethge towardsevidencebasedresponsecriteriaforcancerimmunotherapy

Ejemplares similares